Floatz logo

Oxaliplatin

B-Cell Non-Hodgkin Lymphoma

Explore 306 assets in B-Cell Non-Hodgkin Lymphoma →
Floatz Rating
B61/100
Confidence
Indicative
v0.2
Sponsor
Mwanasha Merrill, MD
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
57High confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT07588698CT.gov
Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma
—Not Yet Recruiting———
NCT07502872CT.gov
TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
—Not Yet Recruiting———
NCT07097363CT.gov
Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
—Recruiting———
NCT07184788CT.gov
G-Pola-GemOx in Refractory/Relapsed Aggressive B-Cell Lymphoma
—Not Yet Recruiting———
NCT07081022CT.gov
JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma
—Recruiting———
NCT06723457CT.gov
Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma
—Active Not Recruiting———
NCT06670105CT.gov
A Phase 2 Trial of Glofitamab for Minimal Residual Disease in Patients With Large B-cell Lymphoma
—Withdrawn———
NCT06806033CT.gov
A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
—Recruiting———
NCT06534437CT.gov
MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)
—Recruiting———
NCT06634589CT.gov
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
—Recruiting———
Show 15 more trials
NCT06393738CT.gov
A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
—Recruiting———
NCT06497452CT.gov
A Study of Efficacy and Safety of Glofitamab in Combination With Salvage Therapy in a Real-world Setting in Chinese Adult Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.
—Recruiting———
NCT06213311CT.gov
A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma
—Recruiting———
NCT05533775CT.gov
A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
—Recruiting———
NCT04970901CT.gov
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
—Recruiting———
NCT05201248CT.gov
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma
—Active Not Recruiting———
NCT04948788CT.gov
SHR1459 in Combination With YY-20394 in Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma
—Unknown———
NCT04161248CT.gov
Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma
—Active Not Recruiting———
NCT04313608CT.gov
A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma
—Completed———
NCT03488251CT.gov
PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma
—Terminated———
NCT03467373CT.gov
A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL
—Completed———
NCT02741388CT.gov
A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP
—Completed———
NCT02055924CT.gov
Bruton's Tyrosine Kinase (BTK) Inhibition in B-cell Lymphomas
—Terminated———
NCT02134262CT.gov
Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes
—Unknown———
NCT01068392CT.gov
Oxaliplatin and Prednisolone (Ox-P) for Patients With Relapsed or Refractory Marginal Zone B-cell Lymphoma(MZL)
—Completed———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · B-Cell Non-Hodgkin Lymphoma

AssetSponsorPhaseRating
Oxaliplatin (this asset)Mwanasha Merrill, MDP2B · 61
VindesineChildren's Cancer Group, ChinaP4BBB
Anti-Cd20/Cd3 Monoclonal Antibody Regn1979University of BirminghamP3BBB
CytarabineChildren's Cancer Group, ChinaP4BBB
CamustineFederal Research Institute of Pediatric Hematology, Oncology and ImmunologyP4BBB
ZanubrutinibThe First Affiliated Hospital of Soochow UniversityP4BBB
IsocyclophosphamideShanghai Junshi Bioscience Co., Ltd.P4BBB
Autologous Cd4+ And Cd8+ T Cells, Enriched From Peripheral Blood Mononuclear Cells (Pbmcs) Transduced With A Nonreplicative Self-Inactivating (Sin) Lentiviral Vector Encoding A Chimeric Antigen Receptor (Car) Consisting Of The Human Cd19-Specific Scfv, An Lgg4 Hinge Region, Cd28 Transmembrane Domain, Cd137 (4-1Bb) Co-Stimulatory Domain And Cd3 Zeta Signalling Domain, Under The Control Of A Hybrid Elongation Factor 1 Alpha (Ef1.Alpha.) And Human T Cell Leukemia Virus Type 1(Htlv-1) Regulatory Element Promoter And Woodchuck Hepatitis Virus Post-Transcriptional Regulatory Element (Wpre). The Vector Genome Also Encodes A Truncated Human Epidermal Growth Factor Receptor (Egfrt) That Is Co-Expressed With The Car And Cleaved From It By The T2A Self-Cleaving Peptide. The Vector Genome Also Contains A Splice Donor, A Fragment Of Gag, A Rev Response Element (Rre), A Mutated Central Polypurine Tract (Cppt), And A Splice AcceptorRuijin HospitalP4BBB
TacrolimusM.D. Anderson Cancer CenterP2BB

+42 more in the B-Cell Non-Hodgkin Lymphoma cohort

Other indications for Oxaliplatin

IndicationSponsorPhaseRating
Exocrine Pancreatic Carcinoma—P2/3BBB · 76
Colon Adenocarcinoma—P3BBB · 76
Colorectal Neoplasm—P4BBB · 74

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Oxaliplatin in B-Cell Non-Hodgkin Lymphoma. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 13, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/oxaliplatin-b-cell-non-hodgkin-lymphoma

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →